DACRA-042 / Eli Lilly, Nordic Biosci  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DACRA-042 / Eli Lilly, Nordic Biosci
NCT03230786 / 2017-001061-24: Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes

Completed
2
255
Europe, RoW
Daily injection of KBP/placebo for 12 weeks as add-on to metformin
KeyBioscience AG, Nordic Bioscience A/S
Type 2 Diabetes Mellitus
07/18
07/18

Download Options